GARFIELD-AF Registry

GARFIELD-AF registry

GARFIELD-AF was the largest prospective registry of patients with newly diagnosed atrial fibrillation

Back to GARFIELD-AF
Keep Up to Date Login
Menu
  • Home

      • The TRI team continues to publish papers based on data accrued during the study (#50 was published in April 2021). Click on a branch of the tree to access the papers associated with that area.

        • Burden of Disease
        • Risk Stratification
        • Treatment Practices
        • Therapy Persistence
        • Clinical Outcomes
        • Geographic Differences
        • Health Economics
  • About
    • About GARFIELD-AF
    • Our Governance
    • About Atrial Fibrillation
    • External Links
  • Risk Calculator
  • Publications & Presentations
  • Newsletters
  • Media
  • Community Page

Asia Pacific Heart Rhythm Society (APHRS) Meeting

Previous Page

APHRS symposium invitation

Joint Meeting of the 10th Asia Pacific Heart Rhythm Society Session (APHRS) and the 64th Annual Meeting of the Japanese Heart Rhythm Society (JHRS)

14 Sep 17 – 17 Sep 17

 

The Thrombosis Research Institute will be presenting data from the GARFIELD-AF registry at the joint meeting of the 10th APHRS and the 64th JHRS which takes place in Yokohama, Japan from 14 to 17 September, 2017.

This will commence with a Teatime Seminar on Thursday 14 September, entitled “Clinical and economic burden of atrial fibrillation (AF) in Asia: real-life data from the GARFIELD-AF registry”, and co-chaired by Professors Shinya Goto and John Camm. The data will be presented by a panel of international speakers from Japan, India, Korea and Singapore, and will cover the following topics:

  • Atrial fibrillation treatment strategies in Asian countries;
  • Stroke prevention in patients with atrial fibrillation and comorbidities;
  • Differences in 1 year event rates between countries in Asia, and
  • Socioeconomic impact of AF – direct and indirect costs attributable to AF (comparison of China vs Japan)

 

Professor Zhi-Cheng Jing, MD, PhD, Professor of Cardiology, FuWai Hospital & State Key Lab of Cardiovascular Disease, Pekin Union will deliver his oral presentation, “Baseline characteristics and treatment patterns in patients with newly diagnosed atrial fibrillation (AF) in Asian countries: Insights from GARFIELD-AF”, also on the first day of Congress highlighting the variations of patient profiles and antithrombotic therapies among Asian countries.

In the same session, Dr Kengo Ayabe, Department of Medicine (Cardiology), Tokai University School of Medicine, Isehara, Japan will deliver his oral presentation, “Risk factor profile and management of patients with diabetes mellitus (DM) and newly diagnosed atrial fibrillation in Asia: results from GARFIELD-AF”. Dr Ayabe’s presentation will highlight the variations in risk profile and anticoagulant use in Asian and non-Asian patients with and without DM, as shown in the global real-world dataset.

On the following day Dr Shinichi Goto, also from Tokai University School of Medicine will deliver his oral presentation, “Risk factor profile and management of patients with chronic kidney disease (CKD) and newly diagnosed atrial fibrillation in Asia: Results from GARFIELD-AF”, focusing on the real-world differences in risk profile and treatment patterns that were observed in Asian and non-Asian AF and CKD patients.

Speaking last month at the ESC Congress 2017 about the global data, Professor Goto commented: “Surprisingly, the use of oral anticoagulants in patients with AF was similar across the stages of CKD even though patients with moderate-to-severe CKD demonstrated a higher risk of stroke/SE, serious bleeding and mortality than those with no CKD. Similar trends were shown in most regions for the three endpoints.”

 

Location: PACIFICO Yokohama Conference Center (Exhibition Hall C), InterContinental Yokohama Grand, 1-1-1, Minato Mirai, Nishi-ku, Yokohama, Japan

Dates: Thursday 14 September 2017 – Sunday 17 September 2017

Previous Page

Community members, please login to view additional information

Global status

Read more
Total patients 57,262
Recruitment Recruitment closed
Follow-up
Study end: 2018

Contact Us

To find out more about GARFIELD-AF, please contact the Thrombosis Research Institute

info@tri-london.ac.uk Contact Us

Follow Us

Keep up to date

Sign up to our newsletter to receive news and updates from us

Keep Up to Date

Funding

The GARFIELD-AF registry was funded by an unrestricted research grant from Bayer AG, and the ongoing work is supported by the Thrombosis Research Institute.

© Copyright TRI 2026

All Rights Reserved. No part of this site may be reproduced without our permission.

  • About TRI
  • Cookie Notice
  • Privacy Policy
  • Terms of Use

Members Login

Coming soon… If you would like to be notified of when this is available click here and add your details to receive updates

Newsletter Signup




    Please see our Privacy Policy and Cookie Policy

    Contact Us

      To find out more about GARFIELD-AF, please contact the Thrombosis Research Institute

      E: garfield@tri-london.ac.uk
      T: 0203 198 9947

      We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.